The impact of amyloid beta burden on white matter dysfunction and associated transcriptomic signatures in cognitively normal elderly individuals
- PMID: 41104121
- PMCID: PMC12522070
- DOI: 10.1002/dad2.70192
The impact of amyloid beta burden on white matter dysfunction and associated transcriptomic signatures in cognitively normal elderly individuals
Abstract
Introduction: Amyloid beta (Aβ), a hallmark of early Alzheimer's disease (AD), disrupts white matter (WM) microstructure, but its spatial patterns and transcriptomic links in cognitively normal individuals remain underexplored.
Methods: We compared the WM microstructure between Aβ-positive (Aβ+) and Aβ-negative (Aβ-) individuals at the cognitively normal stage. We investigated the relationship between the fibers and the cortical and subcortical regions to which they are connected, as well as the underlying gene expression.
Results: WM damage observed in Aβ+ individuals was characterized across eight fiber tracts, even prior to the evidence of atrophy and during the cognitive normal stage. This damage is primarily associated with cortical Aβ accumulation and may be linked to genes that regulate oligodendrocyte function and myelination.
Discussion: Cortical Aβ-related WM changes precede gray matter atrophy in preclinical AD, highlighting their potential as early biomarkers. Oligodendrocyte dysfunction and myelination pathways may underlie Aβ-driven WM vulnerability, offering targets for intervention.
Highlights: WM microstructural changes precede gray matter atrophy in preclinical AD.Aβ-driven WM damage persists even after adjusting for age.WM microstructural damage is primarily linked to cortical Aβ burden in cognitively normal individuals.Oligodendrocytes and myelin underlie the vulnerability of WM-related to Aβ.
Keywords: Alzheimer's disease; amyloid beta; transcriptomics; white matter microstructure.
© 2025 The Author(s). Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
Conflict of interest statement
The authors have no relevant financial or non‐financial interests to disclose.
Figures





References
-
- 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17(3):327‐406. - PubMed
-
- Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid‐β plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669‐678. - PubMed
LinkOut - more resources
Full Text Sources